Table of Contents :
• Stock Rating & Target Price
• Investment Thesis
• Fundamental Models Used
• Company Description
• Corporate Timeline
• Key Metrics (KPI ) and Recently Reported Earnings Review
• Business Highlights, Strategic Announcements & Outlook
• Quarter-over-Quarter (Q-o-Q) and Year-over-Year (Y-o-Y) Growth Analysis
• Key Catalysts Driving Growth
• Historical Financial Statement Analysis & CAGR Trends
• Quarterly Key Financial Ratios and Performance Metrics
• Annual Financial Performance Analysis: Horizontal and Vertical Financial Analysis, Trends
• Financial Forecasts
• Annual Forecasts: Income Statement
• Annual Forecasts: Cash Flow Statements
• Net Debt Levels
• A Closer Look at DCF: Our Assumptions and Methodology
• Terminal Value Calculation
• Target Price Analysis
• Valuation Multiples
• Supplementary Valuation Analysis: Multiples Approach
• Scenario/Sensitivity Analysis – Base Case , Bull Case ,Bear Case
• Holistic Peer Review & Trading Comps: Financial Data, Operational Metrics, and Valuation Multiples
• Implied Price Per Share
• Ownership Activity/ Insider Trades
• Ownership Summary
• An analysis of ESG Risk Rating
• Key Professionals
• Key Board Members
• Key Risks Considerations
• Analyst Ratings
• Analyst Industry Views
• Disclosures
Zoetis Inc.:Innovative Therapies & Expanding Markets To Unlock the Next Chapter of Growth for the Coming 3 Years?- Major Drivers, Thesis & Initiation of Coverage: Forecasts,DCF, Valuation, Peer Analysis, ESG & Risks
Zoetis is making remarkable strides, delivering 12% operational growth in H1 2024, driven by a stellar 16% rise in its companion animal segment and a solid 4% in livestock. Innovative products like Librela and Solensia in pain management, and Apoquel and Cytopoint in dermatology, are leading the charge, with Librela hitting 80% U.S. clinic penetration. Zoetis raised its full-year growth guidance to 9-11%, signaling continued confidence in its robust pipeline, including monoclonal antibodies, CKD, and cardiovascular treatments that could create billion-dollar markets.The company’s disciplined capital allocation, including the divestiture of its MFA business, positions it to focus on high-margin opportunities. Despite headwinds such as competition in parasiticides and pricing pressure in markets like Argentina, Zoetis’ strategic investments in R&D and expanding retail channels will likely drive sustained growth. With the companion animal business on track to comprise over 70% of total revenue in the next five years, Zoetis is poised for long-term expansion. However, challenges in Librela’s adoption due to pricing may slow growth. We see valuation reflects its strong market position, innovation pipeline, and steady growth outlook. Can innovation and strategic focus unlock the next growth chapter? We delve into Major Drivers, Thesis & Initiation of Coverage: Forecasts,DCF, Valuation, Peer Analysis, ESG & Risks
